{"id":9797,"date":"2004-05-02T20:10:18","date_gmt":"2004-05-02T20:10:18","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9797"},"modified":"2014-05-22T17:19:58","modified_gmt":"2014-05-22T17:19:58","slug":"higher-nelfinavir-concentrations-improve-response-in-children","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9797","title":{"rendered":"Higher nelfinavir concentrations improve response in children"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>David Burger from the University Medical Centre in Nijmegen, Holland, presented data from a pharmacokinetic substudy of the PENTA 5 trial, in which na\u00efve children received nelfinavir plus two nucleosides.<\/strong><\/p>\n<p>All participating children received NFV 25-30 mg\/kg TID or 45-55 mg\/kg BID with food. Trough samples were taken between week 20 and 80. NFV troughs &lt;0.8 mg\/L were considered subtherapeutic. Viral load &lt;50 copies\/mL was measured at week 24 and 48.<\/p>\n<p>Forty-four children were enrolled in this substudy of which data from 32 were evaluable (22 boys, 10 girls). The investigators reported an average trough of 2.1mg\/L (n=18; CV: 66%) for children receiving NFV BID and 1.7 mg\/L (n=14; CV 90%) for those receiving the drug TID.<\/p>\n<p>Seven (22%) children had a subtherapeutic NFV trough (0.10-0.53 mg\/L) and the researchers reported no difference between the children with subtherapeutic and therapeutic concentrations with regard to: gender, baseline HIV-1 RNA, daily NFV dose and dose frequency. Viral load less than 50 copies\/mL was reported in 43% and 295 at weeks 24 and 48 respectively.<\/p>\n<p>However of the 25 children with a NFV trough concentration above 0.8mg\/mL, 72% and 80% had HIV RNA &lt;50 copies\/mL at weeks 24 (p=0.20) and 48 (p=0.02) respectively.<\/p>\n<p>The investigators concluded TDM of NFV appears to have the same relevance in children as in adults and a target of 0.8mg\/L improves treatment outcome in children.<\/p>\n<p>Reference:<\/p>\n<p>Burger D, Bergshoeff A, de Groot R et al. Maintaining the nelfinavir trough concentration above 0.8 mg\/L significantly improves virological response in HIV-1-infected children. Abstract 10. Poster 3.3.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base David Burger from the University Medical Centre in Nijmegen, Holland, presented data from a pharmacokinetic substudy of the PENTA 5 trial, in which na\u00efve children received nelfinavir plus two nucleosides. All participating children received NFV 25-30 &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,32,34],"tags":[141],"class_list":["post-9797","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-paediatric-care","category-pk-and-drug-interactions","tag-pk-workshop-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9797"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9797\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}